+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of surgical resection of pulmonary lesions to the relapse of pulmonary aspergillosis in allogeneic hematopoietic stem cell transplant recipients with invasive pulmonary aspergillosis



Effects of surgical resection of pulmonary lesions to the relapse of pulmonary aspergillosis in allogeneic hematopoietic stem cell transplant recipients with invasive pulmonary aspergillosis



Zhonghua Nei Ke Za Zhi 55(1): 31-35



To explore the rate of breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving surgical resection of pulmonary aspergillosis lesions prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). A retrospective analysis was conducted between January 2007 and June 2014. A total of 16 patients were enrolled, who had persistent pulmonary lesions including cavity (diameter >2.0 cm) or mass with a history of IPA prior to allo-HSCT in Nanfang Hospital of Southern Medical University. Ten of the 16 patients underwent thoracoscopic surgery before transplantation, i. e. surgery group, the other 6 patients did not have surgery because of primary underlying diseases (non-complete remission) or multiple lesions i. e. non-surgery group. Secondary prophylactic agents were administrated based on treatment response to initial antigual therapy. The 1-year cumulative and breakthrough rate of IPA, the median time of secondary antifungal prophylaxis (SAP) and overall survival were compared between surgery and non-surgery groups. Within a median follow-up of 364 days after transplantation (range 73 to 400 days). The success rate of SAP was 15/16. The 1-year cumulative and breakthrough IPA were 0 and 0 in surgery group, compared with 3/6 and 1/6 in non-surgery group. The median duration of SAP in surgery group and non-surgery group was 95(74-134)days and 192.5 (56-280)days respectively, which was significantly shorter in surgery group (P=0.017). The overall survival between two groups was 8/10 and 4/6 (P=0.534). No discontinuation of SAP happened in both groups due to drug-related adverse events. In patients with persistent pulmonary IPA lesions, surgical resection followed by SAP might be effective to reduce breakthrough IPA after transplantation with short duration of prophylaxis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057734521

Download citation: RISBibTeXText

PMID: 26796650


Related references

The Serum Galactomannan Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Probable Pulmonary Invasive Aspergillosis. Biology of Blood and Marrow Transplantation 19(2): S288-S289, 2013

Allogeneic hematopoietic stem cell transplantation after surgical resection of pulmonary aspergillosis in 5 patients with acute leukemia. Japanese Journal of Clinical Hematology 50(5): 430-434, 2009

Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. Biology of Blood and Marrow Transplantation 20(8): 1198-1203, 2014

Impact of previous invasive pulmonary aspergillosis on the outcome of allogeneic hematopoietic stem cell transplantation. Korean Journal of Hematology 47(4): 255-259, 2012

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with a History of Prior Invasive Aspergillosis Outcomes and Risks for Post-Transplant Invasive Aspergillosis. Blood 100(11): Abstract No. 2463, 2002

Fulminant Laryngeal-tracheobronchial-pulmonary Aspergillosis: A Rare and Fatal Complication in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Internal Medicine 56(3): 347-351, 2017

Evaluation of late occurring invasive pulmonary aspergillosis after allogeneic hematopoietic stem cell transplantation by high-resolution computed tomography. Blood 102(11): 975a, 2003

Pathological spectrum of invasive pulmonary aspergillosis. Study of pulmonary lesions of 54 autopsies and the relationship between neutrophilic response and histologic features of lesions in experimental aspergillosis. Japanese Journal of Medical Mycology 38(2): 175-181, 1997

Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis. Blood 94(9): 3273-3276, 1999

Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis. Haematologica 97(9): 1357-1363, 2012

The limited role of serum galactomannan assay in screening for invasive pulmonary aspergillosis in allogeneic stem cell transplantation recipients on micafungin prophylaxis: a retrospective study. Blood Research 52(4): 300-306, 2017

Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biology of Blood and Marrow Transplantation 17(7): 1043-1050, 2011

Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder. Journal of ChemoTherapy 19(3): 339-342, 2007

Invasive pulmonary aspergillosis after hematopoietic stem cell transplantation. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 87(3 Suppl 7): 1-6, 2013

Spontaneous Pneumothorax in an Allogeneic Cell Transplant Recipient with Invasive Pulmonary Aspergillosis and Antecedent RSV Pneumonitis. Mediterranean Journal of Hematology and Infectious Diseases 3(1): E20110, 2011